BioCentury

@BioCentury

The leading voice for decision makers throughout the global healthcare ecosystem.

Vrijeme pridruživanja: prosinac 2010.

Medijski sadržaj

  1. prije 13 sati

    After Merck spins out slower-growing businesses to focus on innovation, the company will need recent and future deals to yield fruit in order to balance its reliance on Keytruda for growth

  2. prije 15 sati

    FDA's Richard Pazdur supports expanded access for unapproved uses of approved drugs

  3. prije 15 sati

    EMA hopes to lower barriers to use of real-world data in regulatory decision making by creating a centralized system for integrating RWD across Europe.

  4. 21. sij

    Digital health technologies offer promise for the research and development of new drugs. Register now for the FNIH workshop exploring challenges & opportunities for remote digital monitoring on 2/18-2/19:

  5. 13. sij

    Registration now open for Bio€quity Europe, showcasing 90+ presentations from rising biotechs. Meet our team at

  6. 3. pro 2019.

    We are honored to collaborate with to provide a Korean language version of top BioCentury stories for local biopharma executives and investors. The signing ceremony was held Nov. 25 in Seoul.

  7. 25. stu 2019.

    Congrats to the 2019 BayHelix China Healthcare Award winners, announced last week during the 6th BioCentury-BayHelix China Healthcare Summit in Shanghai.

  8. 13. ruj 2019.

    Early Bird Deadline is Sunday for 6th BioCentury-BayHelix China Healthcare Summit. Record attendance expected. Strategic panels. Road Show track. McKinsey report. 1x1 meetings. Awards banquet. C-suite networking. Register today:

  9. 31. kol 2019.

    This year, BioCentury's Back To School essay argues that it's time for the biopharma industry to write the rules of the road for . Part 1 of

  10. 31. kol 2019.

    The first rule for should be that patients can control who has access to their data and how it can be used, argues in Part 2 of the essay.

  11. 31. kol 2019.

    In , defining what is and isn't regulated will mean re-examining concepts like "identity" and "quality" for products that are continually changing. Part 3 of the essay.

  12. 31. kol 2019.

    In , companies need to go back to first principles to think about placebos, validation, statistical models and more. Part 4 of

  13. 31. kol 2019.

    Case studies on first movers in making inroads into biotech

  14. 31. kol 2019.

    Payers are, like everyone, at square 1 in : the Q for them - what evidence will constitute a measurable benefit?

  15. 31. kol 2019.

    Most pharmas and big biotechs are testing the waters in#digitalhealth and some have taken the full plunge. A snapshot of activity.

  16. 31. kol 2019.

    BioCentury's survey of financing for companies shows over $2 billion raised since 2013 for digital therapeutics, biomarkers and tools for disease management.

  17. 23. kol 2019.

    Build cross-border relationships and find your next strategic partner at the BioCentury-BayHelix China Healthcare Summit. Early-Bird discount ends Sept. 15.

  18. 9. kol 2019.

    Time’s running out for Western biotech execs and investors to register for the BioCentury-BayHelix China Healthcare Summit. This is a unique opportunity to network with key industry stakeholders from China, Asia and the West in an intimate, VIP setting.

  19. 1. kol 2019.

    NewsMakers returns with a program focused on understanding and managing today’s investment risk. Initial slate of Presenting Companies just announced

  20. 8. svi 2019.

    Full program and faculty announced (Barcelona, May 20-21). Register now to learn which EU innovation centers are leading the pack, hear from 80+ hand-picked biotechs, and network with our audience of C-level execs and investment decision makers

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·